Bendamustine-Bortezomib-Dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00074902" target="_blank" >RIV/00216224:14110/14:00074902 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/65269705:_____/14:00061574
Výsledek na webu
<a href="http://dx.doi.org/10.1182/blood-2013-08-521468" target="_blank" >http://dx.doi.org/10.1182/blood-2013-08-521468</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood-2013-08-521468" target="_blank" >10.1182/blood-2013-08-521468</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Bendamustine-Bortezomib-Dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma
Popis výsledku v původním jazyce
Bendamustine with bortezomib and dexamethasone was evaluated in 79 patients with relapsed/refractory multiple myeloma. Median age was 64 (range 40-80) years and patients had a median of 2 (range 1-6) prior treatment lines. Bendamustine 70 mg/m2, day 1 and 4, bortezomib 1.3mg/m2 days 1, 4, 8, 11 intravenously, and dexamethasone 20 mg, days 1, 4, 8, and 11, q 28 days, was given for up to 8 cycles. Primary endpoint was response rate (ORR) and secondary endpoints were progression-free survival (PFS), overall survival (OS), time to response and toxicity. ORR was 60.9%, and when minor responses were included, 75.9%. Median time to response was 31 days (111 to best response). ORR rate was similar in patients previously exposed to bortezomib, lenalidomide andto both bortezomib and lenalidomide. PFS was 9.7 and OS 25.6 months. Multivariate analysis showed high LDH, >/-3 prior treatment lines and low platelet counts correlating with short survival.
Název v anglickém jazyce
Bendamustine-Bortezomib-Dexamethasone is an active and well tolerated regimen in patients with relapsed or refractory multiple myeloma
Popis výsledku anglicky
Bendamustine with bortezomib and dexamethasone was evaluated in 79 patients with relapsed/refractory multiple myeloma. Median age was 64 (range 40-80) years and patients had a median of 2 (range 1-6) prior treatment lines. Bendamustine 70 mg/m2, day 1 and 4, bortezomib 1.3mg/m2 days 1, 4, 8, 11 intravenously, and dexamethasone 20 mg, days 1, 4, 8, and 11, q 28 days, was given for up to 8 cycles. Primary endpoint was response rate (ORR) and secondary endpoints were progression-free survival (PFS), overall survival (OS), time to response and toxicity. ORR was 60.9%, and when minor responses were included, 75.9%. Median time to response was 31 days (111 to best response). ORR rate was similar in patients previously exposed to bortezomib, lenalidomide andto both bortezomib and lenalidomide. PFS was 9.7 and OS 25.6 months. Multivariate analysis showed high LDH, >/-3 prior treatment lines and low platelet counts correlating with short survival.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2014
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Blood
ISSN
0006-4971
e-ISSN
—
Svazek periodika
123
Číslo periodika v rámci svazku
7
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
7
Strana od-do
985-991
Kód UT WoS článku
000335836700013
EID výsledku v databázi Scopus
—